Last reviewed · How we verify
NCT06947018
Impact Evaluation of Türkiye's Adolescent Girls' and Boys' Empowerment Programme for Elimination of Child Marriage
NA trial testing Adolescent Girls' and Boys' Empowerment Program in Marriage Age in 820 participants. Not yet recruiting.
30 October 2025
Quick facts
| Lead sponsor | UNICEF |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 820 |
| Start date | 21 April 2025 |
| Primary completion | 30 October 2025 |
| Estimated completion | 30 October 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Adolescent Girls' and Boys' Empowerment Program
Conditions studied
- Marriage Age — all drugs for Marriage Age →
- Marriage — all drugs for Marriage →
Sponsor
UNICEF — full company profile →
Who can join
Adults 12 to 17, female only, with Marriage Age or Marriage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Low income, refugee, displaced and disaster affected populations face a variety of protection risks, including higher risk of child, early and forced marriage and unions (CEFMU). This is the case in Türkiye, where low income, refugee populations and those affected by the 2023 earthquake in Southern and Central Türkiye face elevated risk of child marriage. As part of the UNICEF Türkiye Country Office (TCO) commitment to implement comprehensive interventions that aim to contribute to a change in social norms and attitudes towards gender equality, the CO and partners have developed the "Adolescent Girls' and Boys' Empowerment for Elimination of Child Marriage" program (hereafter "the program"). The program is an 8-week group-based empowerment and life skills training for adolescent girls aged 12 - 18 years old, a 4-session adolescent boys awareness training, and a one-time awareness raising seminar for caregivers. The current trial has the overall objective of evaluating the short-term causal impact of the program with respect to CEFMU and related outcomes for adolescent girls. The trial design is an individual randomized control trial, allocating 820 households with adolescent girls to either treatment or control on a 1:1 basis. The primary data collection includes a pre- and post-intervention caregiver and adolescent face-to-face survey, as well as a one-time qualitative data collection. The trial results will inform the future operation and scale-up of the program, as well as contribute to the broader evidence base on what works to increase the empowerment of adolescent girls and reduce CEFMU.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06947018
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other UNICEF trials
Trials by the same sponsor.
- NCT04491994 — Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression · Phase 3 · completed
- NCT04485169 — Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm; · NA · completed
- NCT04492501 — Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06947018 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by UNICEF
- Last refreshed: 27 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06947018.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing